RT Journal Article
SR Electronic
T1 Management of Cardiac Adverse Events Occurring with Sunitinib Treatment
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1627
OP 1629
VO 29
IS 5
A1 SCHMIDINGER, MANUELA
A1 BOJIC, ANDJA
A1 VOGL, URSULA M
A1 LAMM, WOLFGANG
A1 ZIELINSKI, CHRISTOPH C.
YR 2009
UL http://ar.iiarjournals.org/content/29/5/1627.abstract
AB Background: Sunitinib malate is the reference standard of care for the first-line treatment of metastatic renal cell carcinoma (mRCC). Cardiovascular adverse events (AEs) have been observed with sunitinib treatment. Here, we present the case report of a 49-year-old male patient with mRCC in whom cardiac AEs experienced during sunitinib treatment were successfully managed. The patient was at poor prognostic risk, with an Eastern Cooperative Oncology Group performance status of 3. Results: The patient was treated with sunitinib 50 mg/day (4 weeks on treatment followed by 2 weeks off treatment; Schedule 4/2) following lung and bone metastases. Cardiac AEs occurred following sunitinib initiation. These events were resolved with cardiovascular co-medication. Sunitinib improved the patient's quality of life and performance status, with a prolonged duration of treatment of 24 months. Conclusion: This case indicates that cardiac AEs should not be a barrier to the effective use of sunitinib in mRCC.